Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Author:
Shu Chao QIN
1
;
Rui JIANG
1
;
Ye Qin SHA
1
;
Jing Yan QIU
2
;
Hong Ling MI
2
;
Yi MIAO
1
;
Wei WU
1
;
Li WANG
1
;
Lei FAN
1
;
Wei XU
1
;
Jian Yong LI
1
;
Hua Yuan ZHU
1
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Rituximab/therapeutic use*; Bendamustine Hydrochloride/therapeutic use*; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*; Lymphoma, B-Cell; Protein Kinase Inhibitors/therapeutic use*; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome
- From: Chinese Journal of Hematology 2023;44(2):158-161
- CountryChina
- Language:Chinese
